Sinai GLP-1 scientist Daniel Drucker (32.3k X followers) noted ongoing Phase 3 trials from Novo Nordisk as probably the most risky trial that we have ever undertaken, signaling caution amidst patient optimism (1.6k X views)
My life has been marked by significant periods of weight loss and gain, for nearly 30 years
A placebo-controlled clinical trial demonstrated that a peptide serum containing SNAP-8 led to a significant reduction in expression lines and overall improvement in skin texture
In a 12-week preliminary RCT, patients with obesity on GLP-1RA following a diet consisting of 1.3 g/kg protein successfully promoted fat mass reduction while preserving fat free mass, muscle strength, and resting metabolic rate compared to those following a traditional isocaloric diet [57]
Positive Phase III pivotal data is the second, and typically the largest single value step
Lancet 394 (10212), 19491964